title: [Experience with high-dose chemotherapy in patients with testicular diffuse large B-cell lymphoma].
abstract: OBJECTIVE
  To evaluate the efficiency of high-dose therapy according to the DLBL-CNS-2007 protocol in patients with testicular diffuse large B-cell lymphoma (DLBL).
  
  
  METHODS
  Out of 408 male patients with non-Hodgkin lymphoma, 8 patients aged 50 to 69 years (median age 55.5 years) with primary testicular (n=3) or with generalized-stage testicular DLBL (n=5) were included in the study. These patients were followed up at the Hematology Research Center, Ministry of Health of the Russian Federation, in 2007 to 2013. Systemic chemotherapy was performed in accordance with the DLBL-CNS-2007 protocol.
  
  
  RESULTS
  The DLBL-CNS-2007 protocol was implemented in first-line therapy in 7 patients. At the first diagnostic stage, one patient was found to have anaplastic seminoma; in this connection right orchifuniculectomy was carried out, followed by radiotherapy applied to the scrotal region in a total focal dose of 34 Gy. This patient with disease recurrence was included in the DLBL-CNS-2007 treatment protocol. The number of polychemotherapy (PCT) cycles (n=4 or 6) was determined by the time to achieve complete remission. After completion of DLBL-CNS-2007 PCT, 6 patients achieved complete remission; the primary resistant disease was noted in 2 cases. At this moment 6 patients are alive in first complete remission during the median follow-up of 50 months (10-54 months).
  
  
  CONCLUSIONS
  The findings suggest that high-dose therapy according to the DLBL-CNS-2007 protocol in patients with testicular DLBL can achieve complete remission and increase overall and event-free survival rates. This fact should be borne out by a large number of observations.
authors.forename: E S
authors.initials: ES
authors.lastname: Nesterova
authors.forename: Ia K
authors.initials: IaK
authors.lastname: Mangasarova
authors.forename: E A
authors.initials: EA
authors.lastname: Bariakh
authors.forename: A V
authors.initials: AV
authors.lastname: Gubkin
authors.forename: T N
authors.initials: TN
authors.lastname: Tolstykh
authors.forename: A I
authors.initials: AI
authors.lastname: Lukina
authors.forename: A M
authors.initials: AM
authors.lastname: Kovrigina
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: N G
authors.initials: NG
authors.lastname: Chernova
authors.forename: D S
authors.initials: DS
authors.lastname: Mar'in
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: É G
authors.initials: ÉG
authors.lastname: Gemdzhian
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D017809:Fatal Outcome; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018239:Seminoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome